The ExCel breast cancer prevention study is back. ExCel was short-circuited before it really got started last year because a study arm included the cox-2 inhibitor celecoxib (Celebrex) that was suddenly pulled off the market due to side effects.
Baxter International Inc. announced today that its European subsidiary has received a contract from the National Health Service (NHS) in the United Kingdom to produce a stockpile of two million doses of candidate H5N1 influenza vaccine based on an avian strain. Under the agreement, Baxter will complete delivery of the stockpile [...]
Sigma-Aldrich, a leading $1.7 billion Life Science company, is pleased to announce the latest addition to its Panorama(TM) Protein Array product line, the Panorama(TM) Human Kinase v1 Array. Developed in conjunction with Procognia Ltd, UK, and licensed exclusively through Sigma-Aldrich, the Kinase v1 protein array contains 152 commonly studied kinases.
America’s Blood Centers (ABC) and Minnesota Thermal Science, LLC have announced a partnership agreement to enable ABC members to use Golden Hour Technology as the preferred method for shipping blood and blood products.
Novo Nordisk, a leader in breakthrough hemostasis research and treatment, was joined today by New Jersey government officials to inaugurate Novo Nordisk Research US, the first hemostasis research facility in the United States dedicated to life- threatening bleeding. The company celebrated the opening of the facility as well as its Danish [...]
Nabi Biopharmaceuticals reported today that total revenues for the full year ended December 31, 2005 were $108.1 million compared to $179.8 million in 2004. A decrease in revenues was expected and was primarily driven by the March 2005 expiration of a ten-year agreement to distribute WinRho SDF ([Rho(D) Immune Globulin (Human)] [...]
Cardiac Science Corporation , a global leader in advanced cardiac monitoring and defibrillation products, today announced results for the quarter ended December 31, 2005, reporting pro forma net income of $0.1 million and pro forma revenue growth of 9% over the third quarter of 2005.
Ferring Pharmaceuticals Inc. announced today that Olympic gold medal winner Bruce Jenner will be serving as the national spokesperson for the company’s newest product, EUFLEXXA(TM) (highly purified hyaluronan). The announcement comes as Jenner celebrates the 30th anniversary of his remarkable achievements at the 1976 Olympic Games in Montreal. There, Jenner earned the title of “World’s [...]
EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammation, today announced the issuance of U.S. Patent No. 6,995,278 covering analogs of its lead compound, 2-methoxyestradiol (2ME2 or Panzem(R)). Panzem(R) is currently in clinical trials for cancer, as well as in preclinical development for inflammatory disorders.
Advanced Medical Optics, Inc. (AMO)Â , a global leader in ophthalmic surgical devices and eye care products, today announced financial results for the fourth quarter and full year of 2005.